Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 10/20 | 0.36 |
| ▸ | MAOA | P21397 | 9/20 | 0.36 |
| ▸ | MAOB | P27338 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18624657 | 0.84 | NPSR1 (0.36) | ATMNPSR1HTTLMNAKDM1A | |
| SCHEMBL17414380 | 0.78 | ATM (0.38) | ATMNPSR1HTTLMNAKDM1A | |
| SCHEMBL18624655 | 0.78 | ATM (0.38) | ATMNPSR1HTTLMNAKDM1A | |
| SCHEMBL17414366 | 0.70 | CHRNB2 (0.38) | ATMNPSR1HTTLMNAKDM1A | |
| SCHEMBL19214521 | 0.67 | TRPA1 (0.41) | KDM1AMAOAMAOBALDH1A1TRPA1 | |
| SCHEMBL4349095 | 0.60 | TRPA1 (0.47) | HTTKDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL14065397 | 0.60 | CHRNB2 (0.44) | MAOAMAOBALDH1A1MEN1KMT2A | |
| SCHEMBL14095714 | 0.59 | SMN1; SMN2 (0.33) | MAOAMAOBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14223522 | 0.59 | ALDH1A1 (0.43) | ATMNPSR1HTTLMNAALDH1A1 | |
| SCHEMBL13823143 | 0.58 | TRPA1 (0.41) | LMNAKDM1AMAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487472-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160002145-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002145-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | ATM 2965/4885NPSR1 853/4885HTT 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.